Restoration of wild-type PTEN expression leads to apoptosis, induces differentiation, and reduces telomerase activity in human glioma cells

Journal of Neuropathology and Experimental Neurology

Volumn 58, Issue 5, 1999, Pages 472-479

  Tian, Xin Xia ^a   Pang, Jesse C S ^a   To, Shing Shun T ^b   Ng, Ho Keung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b NONE

Author keywords

Apoptosis; Differentiation; Glioma; Proliferation; PTEN; Telomerase

Indexed keywords

TELOMERASE;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CHROMOSOME 10Q; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GLIOMA CELL; GROWTH INHIBITION; HOMEOSTASIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0032925793     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199905000-00006     Document Type: Article

References (29)

1. Von Deimling A. Molecular genetic classification of astrocytic and oligodendroglial tumors. Brain Pathol 1997;7:1311-13
2. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 1997;275:1943-47
3. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumor suppressor gene at 10q23.3 that is mutated in multiple advanced cancers, MMAC1. Nat Genet 1998;15:356-62
4. Li DM, Sun H. TEP1, encoded by a candidate tumour suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor-beta. Cancer Res 1997;57:2124-29
5. Teng DHF, Hu R, Lin H, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997;57: 5221-25
6. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-40
7. Wang SI, Pue J, Li J, et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer res 1997;57:4183-86
8. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16:64-67
9. Nelen MR, van Staveren CG, Peeters EAJ, et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 1997;6:1383-87
10. Marsh DJ, Dahia PLM, Zheng Z, et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 1997;16:333-34
11. Olschwang S, Serova-Sinilnikova OM, Lenoir GM, Thomas G. PTEN germ-line mutations in juvenile polyposis coli. Nat Genet 1998;18:12-14
12. Cristofano AD, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998;4:348-55
13. Stambolic V, Suzuki A, de la Pompa, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39
14. Furnari FB, Lin H, Huang HJS, Cavenee WK. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA 1997;94:12479-84
15. Cheney IW, Johnson DE, Vaillancourt MT, et al. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res 1998;58:2331-34
16. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998;280:1614-17
17. Myers MP, Stolarov JP, Eng C, et al. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA 1997;94:9052-57
18. Tian XX, Lam PYP, Chen J, et al. Antisense epidermal growth factor receptor RNA transfection in human malignant glioma cells leads to inhibition of proliferation and induction of differentiation. Neuropath Appl Neurobiol 1998;24:389-96
19. Chong EYY, Lam PYP, Poon WS, Ng HK. Telomerase expression in gliomas including the nonastrocytic tumors. Hum Pathol 1998;29:599-603
20. Rutka JT, DeArmond SJ, Giblin JR, McCulloch JR, Wilson CB, Rosenblum ML. Effect of retinoids on the proliferation, morphology and expression of GFAP of an anaplastic astrocytoma cell line. Int J Cancer 1988;42:419-27
21. Engelhard HH, Duncan HA, Dal Canto M. Molecular characterization of glioblastoma cell differentiation. Neurosurg 1997;41: 886-97
22. Merzak A, Raynal S, Rogers JP, Lawrence D, Pilkington GJ. Human wild-type p53 inhibits cell proliferation and elicits dramatic morphological changes in human glioma cell lines in vitro. J Neurol Sci 1994;127:125-33
23. Duffy PE, Huang YY, Rapport MM. The relationship of GFAP to the shape, motility, and differentiation of human astrocytoma cells. Exp Cell Res 1982;139:145-57
24. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-triphosphate. J Biol Chem 1998;273:13375-78
25. Myers MP, Pass I, Batty IH, et al. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc Natl Acad Sci USA 1998;95:13513-18
26. Haas-Kogan D, Shalev N, Wong M, Mills O, Yount G, Stokoe D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Cancer Res 1998;58:1195-98
27. Duronio V, Scheid MP, Ettinger S. Downstream signalling events regulated by phosphatidylinositol 3-kinase activity. Cell Signal 1998;10:233-39
28. Marte BM Downward J. PKB/Akt: connecting phosphinositide 3-kinase to cell survival and beyond. Trends Biochem Sci 1997;22: 355-58
29. Kondo S, Tanaka Y, Kondo Y, et al. Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation. FASEB J 1998;12:801-11